| Aradigm is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Co.'s primary development candidates are proprietary formulations of the potent antibiotic ciprofloxacin (Linhaliq (ARD-3150) and Lipoquin® (ARD-3100)) that are delivered by inhalation for the management of infections associated with severe respiratory diseases such as non-cystic fibrosis bronchiectasis and cystic fibrosis. The formulations differ in the proportion of rapidly available and slow release ciprofloxacin. Co. is also investigating the treatment of pulmonary non-tuberculous mycobacteria infections. We show 20 historical shares outstanding datapoints in our ARDM shares outstanding history coverage, used to compute ARDM market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ARDM market cap history over the course of time is important for investors
interested in comparing ARDM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ARDM versus a peer is one thing; comparing
ARDM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ARDM can fluctuate over the course of history.
With this page we aim to empower investors researching ARDM by allowing them to research the ARDM market cap history.